A Comprehensive Overview of US-FDA-Approved Anticancer Drugs and Biologics in 2023: An Observational Study.
- Published in:
- Journal of Pharmacy & Bioallied Sciences, 2025, v. 17, n. 1, p. 27, doi. 10.4103/jpbs.jpbs_730_25
- By:
- Publication type:
- Article
Works matching IS 09764879 AND DT 2025 AND VI 17 AND IP 1
Results: 5
1
2
Awareness, Preparedness, and Practices of Hospital Staff During COVID-19 Pandemic in Saudi Arabia: Lessons Learned.
- Published in:
- Journal of Pharmacy & Bioallied Sciences, 2025, v. 17, n. 1, p. 19, doi. 10.4103/jpbs.jpbs_148_25
- By:
- Publication type:
- Article
3
Relationship of Fingerprints with Blood Group and Sex—A Comparative Study.
- Published in:
- Journal of Pharmacy & Bioallied Sciences, 2025, v. 17, n. 1, p. 14, doi. 10.4103/jpbs.jpbs_1120_24
- By:
- Publication type:
- Article
4
Observational Study on Hematological Adverse Drug Reactions (HADRs) from Hydroxyurea in Pediatric Patients with Sickle Cell Disease (SCD): Assessing Prevalence, Causality, Severity, Preventability, and Predictability, along with Clinical Management by a Clinical Pharmacist at a Tertiary Care Teaching Hospital
- Published in:
- Journal of Pharmacy & Bioallied Sciences, 2025, v. 17, n. 1, p. 6, doi. 10.4103/jpbs.jpbs_482_24
- By:
- Publication type:
- Article
5
A Hospital-Based Analytical Study on Antibiotic Utilization in Pediatric Patients and Antibiotic Stewardship.
- Published in:
- Journal of Pharmacy & Bioallied Sciences, 2025, v. 17, n. 1, p. 1, doi. 10.4103/jpbs.jpbs_485_24
- By:
- Publication type:
- Article